ATE290879T1 - Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung - Google Patents
Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendungInfo
- Publication number
- ATE290879T1 ATE290879T1 AT00957617T AT00957617T ATE290879T1 AT E290879 T1 ATE290879 T1 AT E290879T1 AT 00957617 T AT00957617 T AT 00957617T AT 00957617 T AT00957617 T AT 00957617T AT E290879 T1 ATE290879 T1 AT E290879T1
- Authority
- AT
- Austria
- Prior art keywords
- muc
- antigen
- antibodies against
- therapeutic antibodies
- therapeutic compositions
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 102100034256 Mucin-1 Human genes 0.000 title abstract 3
- 108010008707 Mucin-1 Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US16471499P | 1999-11-11 | 1999-11-11 | |
| PCT/US2000/022890 WO2001012217A1 (en) | 1999-08-18 | 2000-08-18 | Therapeutic antibody against muc-1 antigen and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290879T1 true ATE290879T1 (de) | 2005-04-15 |
Family
ID=26846783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00957617T ATE290879T1 (de) | 1999-08-18 | 2000-08-18 | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (de) |
| JP (2) | JP2003519096A (de) |
| AT (1) | ATE290879T1 (de) |
| AU (1) | AU782569B2 (de) |
| DE (1) | DE60018761T2 (de) |
| ES (1) | ES2239032T3 (de) |
| WO (1) | WO2001012217A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| US20020110841A1 (en) | 2000-12-22 | 2002-08-15 | KUFE Donald W. | Regulation of cell growth by MUC1 |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| JP2004529091A (ja) * | 2001-01-30 | 2004-09-24 | アルタケム・ファーマ・リミテッド | 免疫療法剤と共に使用するためのペリレンキノン |
| CA2441809C (en) | 2001-03-27 | 2014-07-22 | Biomira, Inc. | Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses |
| GB2397018B (en) * | 2001-10-26 | 2006-05-31 | Altarex Medical Corp | Combination therapy for treating disease |
| TR200401834T2 (tr) * | 2002-01-24 | 2005-10-21 | Barnes-Jewish Hospital | İntegrin hedefli görüntüleme etken maddeleri. |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| AU2006209246A1 (en) * | 2005-01-28 | 2006-08-03 | Biomodifying Llc | Anti-MUC1 alpha/beta antibodies |
| JP5364371B2 (ja) | 2005-06-28 | 2013-12-11 | オンコセリオン インコーポレイテッド | ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法 |
| AU2006279189B2 (en) | 2005-08-10 | 2011-08-04 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| EP2428224B1 (de) | 2006-09-10 | 2016-12-21 | Glycotope GmbH | Verwendung von menschlichen zellen von myeloischer leukämie zur expression von antikörpern |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| CA2741798A1 (en) | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anti-muc1 antibody |
| EP2281844A1 (de) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC-1-Antikörper |
| JP5916017B2 (ja) | 2010-04-28 | 2016-05-11 | 塩野義製薬株式会社 | 新規なｍｕｃ１抗体 |
| JP2014518841A (ja) | 2011-02-24 | 2014-08-07 | オンコシレオン インク． | アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン |
| JP6148671B2 (ja) | 2011-08-22 | 2017-06-14 | グリコトープ ゲーエムベーハー | 腫瘍抗原を保有する微生物 |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| RU2016144178A (ru) | 2014-04-28 | 2018-05-10 | Медисинал Кемистри Фармасьютикалс, Ко., Лтд. | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение |
| EP3574015A1 (de) * | 2017-01-27 | 2019-12-04 | Glycotope GmbH | Antikrebsbehandlungen mit einem anti-muc1-antikörper und einem erbb-inhibitor |
| EP4249002A3 (de) | 2018-05-18 | 2023-11-22 | Daiichi Sankyo Co., Ltd. | Conjugue agent cytotoxique et anticorps anti-muc1-exatecan |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2118010C (en) * | 1992-04-13 | 2003-10-28 | Donald Kufe | Antibodies specific for carcinoma-associated antigens |
| JPH08505119A (ja) * | 1992-07-06 | 1996-06-04 | バイオミラ、インコーポレーテッド | 接合目的のためのタンパク質の光活性化 |
| AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| WO1997042973A1 (en) * | 1996-05-15 | 1997-11-20 | Altarex, Corp. | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| CA2277362A1 (en) * | 1997-01-10 | 1998-08-06 | Altarex Corp. | Substituted perylenequinones for use in photodynamic therapy |
| JP2002502621A (ja) * | 1998-02-13 | 2002-01-29 | バステルト・ギュンター | 乳腫瘍を伴うムチンに対する特異性のある抗体、その生産方法及び使用方法 |
-
2000
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 EP EP00957617A patent/EP1204423B1/de not_active Expired - Lifetime
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en active IP Right Grant
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1204423A1 (de) | 2002-05-15 |
| WO2001012217A9 (en) | 2002-06-27 |
| JP2012046518A (ja) | 2012-03-08 |
| DE60018761D1 (de) | 2005-04-21 |
| AU782569B2 (en) | 2005-08-11 |
| AU6921100A (en) | 2001-03-13 |
| WO2001012217A1 (en) | 2001-02-22 |
| JP2003519096A (ja) | 2003-06-17 |
| DE60018761T2 (de) | 2006-02-02 |
| ES2239032T3 (es) | 2005-09-16 |
| EP1204423B1 (de) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290879T1 (de) | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| NO331072B1 (no) | Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme. | |
| DK1383785T3 (da) | Rekombinant tumorspecifikt antistof og anvendelse deraf | |
| SI1572087T1 (sl) | Protitelesa proti antigenu tmeff2 raka in njihovauporaba | |
| EP1476120A4 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
| PL377337A1 (pl) | Humanizowane przeciwciało (H14.18) z mysiego przeciwciała 14.18 wiążące GD2 oraz jego połączenie z IL-2 | |
| IL139700A0 (en) | Immunotherapeutic composition and method for the treatment of prostate cancer | |
| DE69531679D1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
| EP2298333A3 (de) | Tweak Rezeptor | |
| EP1355563A4 (de) | VERFAHREN ZUR PRÄVENTION UND BEHANDLUNG VON KREBS MIT ANTI-C3B(i)-ANTIKÖRPERN | |
| DE69433406T2 (de) | Antikörper gegen cd40 | |
| DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
| DK1782070T3 (da) | Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi | |
| EE04752B1 (et) | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine | |
| BR9612619A (pt) | Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica | |
| ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
| EP1581096A4 (de) | Antigen-pipa und daran bindende antikörper | |
| ATE490785T1 (de) | Parathormon-antikörper und damit zusammenhängende verfahren | |
| TW200517124A (en) | Fully human antibodies against human 4-1BB | |
| AU7299591A (en) | Delivery of agents | |
| DE3485712D1 (de) | Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren. | |
| GB0102145D0 (en) | Substances | |
| AU2003293665A1 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1204423 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee | ||
| EEWE | Authorization for restitution |